Axillary staging prior to neoadjuvant chemotherapy: The roles of sentinel lymph node biopsy and axillary ultrasonography

Cancer Control

Volumn 19, Issue 4, 2012, Pages 277-285

  Lee Dr , Marie Catherine ^a,b   Joh, Jennifer E ^a   Chau, Alec ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INDOCYANINE GREEN; ISOSULFAN BLUE; METHYLENE BLUE; TECHNETIUM SULFUR COLLOID TC 99M;

ADJUVANT THERAPY; ARTICLE; AXILLARY LYMPH NODE; BIOPSY TECHNIQUE; BREAST CANCER; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; ECHOGRAPHY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT SAFETY; PERCUTANEOUS BIOPSY; PREOPERATIVE EVALUATION; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY;

EID: 84866973734     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481201900404     Document Type: Article

References (83)

1. Specht MC, Fey JV, Borgen PI, et al. Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy? J Am Coll Surg. 2005;200(1):10-14.
2. Lanng C, Hoffmann J, Galatius H, et al. Assessment of clinical palpation of the axilla as a criterion for performing the sentinel node procedure in breast cancer. Eur J Surg Oncol. 2007;33(3):281-284.
3. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672-2685.
4. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in earlystage breast cancer. J Clin Oncol. 2005;23(30):7703-7720.
5. Kilbride KE, Lee MC, Nees AV, et al. Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence. Ann Surg Oncol. 2008; 15(11):3252-3258.
6. Batsis C, Ziogas D, Fatouros M. Neoadjuvant chemotherapy for breast cancer: does pretreatment axillary nodal staging improve decision making? Ann Surg Oncol. 2009;16(4):1063-1064.
7. Buchholz TA, Lehman CD, Harris JR, et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol. 2008;26(5):791-797.
8. Brancato B, Zappa M, Bricolo D, et al. Role of ultrasound-guided fine needle cytology of axillary lymph nodes in breast carcinoma staging. Radiol Med. 2004;108(4):345-355.
9. Ciatto S, Brancato B, Risso G, et al. Accuracy of fine needle aspiration cytology (FNAC) of axillary lymph nodes as a triage test in breast cancer staging. Breast Cancer Res Treat. 2007;103(1):85-91.
10. Davis JT, Brill YM, Simmons S, et al. Ultrasound-guided fine-needle aspiration of clinically negative lymph nodes versus sentinel node mapping in patients at high risk for axillary metastasis. Ann Surg Oncol. 2006;13(12):1545-1552.
11. de Kanter AY, van Eijck CH, van Geel AN, et al. Multicentre study of ultrasonographically guided axillary node biopsy in patients with breast cancer. Br J Surg. 1999;86(11):1459-1462.
12. Genta F, Zanon E, Camanni M, et al. Cost/accuracy ratio analysis in breast cancer patients undergoing ultrasound-guided fine-needle aspiration cytology, sentinel node biopsy, and frozen section of node. World J Surg. 2007;31(6):1155-1163.
13. Hinson JL, McGrath P, Moore A, et al. The critical role of axillary ultrasound and aspiration biopsy in the management of breast cancer patients with clinically negative axilla. Ann Surg Oncol. 2008;15(1):250-255.
14. Krishnamurthy S, Sneige N, Bedi DG, et al. Role of ultrasound-guided fineneedle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer. 2002;95(5):982-988.
15. Sapino A, Cassoni P, Zanon E, et al. Ultrasonographically-guided fineneedle aspiration of axillary lymph nodes: role in breast cancer management. Br J Cancer. 2003;88(5):702-706.
16. Tahir M, Osman KA, Shabbir J, et al. Preoperative axillary staging in breast cancer-saving time and resources. Breast J. 2008;14(4):369-371.
17. van Rijk MC, Deurloo EE, Nieweg OE, et al. Ultrasonography and fineneedle aspiration cytology can spare breast cancer patients unnecessary sentinel lymph node biopsy. Ann Surg Oncol. 2006;13(1):31-35.
18. Tate JJ, Lewis V, Archer T, et al. Ultrasound detection of axillary lymph node metastases in breast cancer. Eur J Surg Oncol. 1989;15(2):139-141.
19. Mustonen P, Farin P, Kosunen O. Ultrasonographic detection of metastatic axillary lymph nodes in breast cancer. Ann Chir Gynaecol. 1990;79(1):15-18.
20. Walsh JS, Dixon JM, Chetty U, et al. Colour Doppler studies of axillary node metastases in breast carcinoma. Clin Radiol. 1994;49(3):189-191.
21. Bonnema J, van Geel AN, van Ooijen B, et al. Ultrasound-guided aspiration biopsy for detection of nonpalpable axillary node metastases in breast cancer patients: new diagnostic method. World J Surg. 1997;21(3):270-274.
22. Garcia-Ortega MJ, Benito MA, Vahamonde EF, et al. Pretreatment axillary ultrasonography and core biopsy in patients with suspected breast cancer: diagnostic accuracy and impact on management. Eur J Radiol. 2011;79(1):64-72.
23. Lee MC, Eatrides J, Chau A, et al. Consequences of axillary ultrasound in patients with T2 or greater invasive breast cancers. Ann Surg Oncol. 2011;18(1):72-77.
24. Blumgart EI, Uren RF, Nielsen PM, et al. Predicting lymphatic drainage patterns and primary tumour location in patients with breast cancer. Breast Cancer Res Treat. 2011;130(2):699-705.
25. van der Ent FW, Kengen RA, van der Pol HA, et al. Halsted revisited: internal mammary sentinel lymph node biopsy in breast cancer. Ann Surg. 2001;234(1):79-84.
26. van Rijk MC, Tanis PJ, Nieweg OE, et al. Clinical implications of sentinel nodes outside the axilla and internal mammary chain in patients with breast cancer. J Surg Oncol. 2006;94(4):281-286.
27. Stavros AT, ed. Breast Ultrasound. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.
28. Bedi DG, Krishnamurthy R, Krishnamurthy S, et al. Cortical morphologic features of axillary lymph nodes as a predictor of metastasis in breast cancer: in vitro sonographic study. AJR Am J Roentgenol. 2008;191(3):646-652.
29. Vassallo P, Wernecke K, Roos N, et al. Differentiation of benign from malignant superficial lymphadenopathy: the role of high-resolution US. Radiology. 1992;183(1):215-220.
30. Raza S. Axillary adenopathy. In: Berg W, ed. Diagnostic Imaging: Breast. Vol. IV. Salt Lake City, UT: Amirsys; 2008:30-31.
31. Cho N, Moon WK, Han W, et al. Preoperative sonographic classification of axillary lymph nodes in patients with breast cancer: node-to-node correlation with surgical histology and sentinel node biopsy results. AJR Am J Roentgenol. 2009;193(6):1731-1737.
32. Joh J, Han G, Kiluk JV, et al. Features associated with abnormal axillary ultrasound in breast cancer. Paper presented at the American Society of Breast Surgeons 12th Annual Meeting; April 27-May 1, 2011; Washington, DC.
33. Johnson S, Brown S, Porter G, et al. Staging primary breast cancer: are there tumour pathological features that correlate with a false-negative axillary ultrasound? Clin Radiol. 2011;66(6):497-499.
34. Mainiero MB, Cinelli CM, Koelliker SL, et al. Axillary ultrasound and fineneedle aspiration in the preoperative evaluation of the breast cancer patient: an algorithm based on tumor size and lymph node appearance. AJR Am J Roentgenol. 2010;195(5):1261-1267.
35. Baruah BP, Goyal A, Young P, et al. Axillary node staging by ultrasonography and fine-needle aspiration cytology in patients with breast cancer. Br J Surg. 2010;97(5):680-683.
36. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294(8):405-410.
37. McArdle CS, Crawford D, Dykes EH, et al. Adjuvant radiotherapy and chemotherapy in breast cancer. Br J Surg. 1986;73(4):264-266.
38. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365 (9472):1687-1717.
39. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483-2493.
40. Bonadonna G, Moliterni A, Zambetti M, et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ. 2005;330(7485):217.
41. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24(12):1940-1949.
42. Weiss RB, Woolf SH, Demakos E, et al. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. J Clin Oncol. 2003;21(9):1825-1835.
43. Boughey JC, Moriarty JP, Degnim AC, et al. Cost modeling of preoperative axillary ultrasound and fine-needle aspiration to guide surgery for invasive breast cancer. Ann Surg Oncol. 2010;17(4):953-958.
44. Turaga KK, Chau A, Eatrides JM, et al. Selective application of routine preoperative axillary ultrasonography reduces costs for invasive breast cancers. Oncologist. 2011;16(7):942-948.
45. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569-575.
46. Polom K, Murawa D, Nowaczyk P, et al. Breast cancer sentinel lymph node mapping using near infrared guided indocyanine green and indocyanine greenhuman serum albumin in comparison with gamma emitting radioactive colloid tracer. Eur J Surg Oncol. 2012;38(2):137-142.
47. Hirche C, Mohr Z, Kneif S, et al. High rate of solitary sentinel node metastases identification by fluorescence-guided lymphatic imaging in breast cancer. J Surg Oncol. 2012;105(2):162-166.
48. Mieog JS, Troyan SL, Hutteman M, et al. Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer. Ann Surg Oncol. 2011;18(9):2483-2491.
49. Niu C, Wang Z, Zuo G, et al. Poly(lactide-co-glycolide) ultrasonographic microbubbles carrying sudan black for preoperative and intraoperative localization of lymph nodes. Clin Breast Cancer. 2012;12(3):199-206.
50. Tafreshi NK, Enkemann SA, Bui MM, et al. A mammaglobin-A targeting agent for noninvasive detection of breast cancer metastasis in lymph nodes. Cancer Res. 2011;71(3):1050-1059.
51. Papa MZ, Zippel D, Kaufman B, et al. Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer. J Surg Oncol. 2008;98(6):403-406.
52. Cox CE, Cox JM, White LB, et al. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer. Ann Surg Oncol. 2006;13(4):483-490.
53. Shen J, Gilcrease MZ, Babiera GV, et al. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer. 2007;109(7):1255-1263.
54. Newman E, Sabel M, Nees A, et al. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented nodepositive breast cancer at presentation. Ann Surg Oncol. 2007;14(10):2946-2952.
55. Cohen LF, Breslin TM, Kuerer HM, et al. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol. 2000;24(9):1266-1272.
56. Pecha V, Kolarik D, Kozevnikova R, et al. Sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy. Cancer. 2011 Mar 22. [Epub ahead of print]
57. Schwartz GF, Tannebaum JE, Jernigan AM, et al. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast. Cancer. 2010;116(5):1243-1251.
58. Tausch C, Konstantiniuk P, Kugler F, et al. Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Study Group. Ann Surg Oncol. 2008;15(12):3378-3383.
59. Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000;18(20): 3480-3486.
60. Classe JM, Bordes V, Campion L, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol. 2009;27(5):726-732.
61. Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250(4):558-566.
62. Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23(12):2694-2702.
63. Rebollo-Aguirre AC, Gallego-Peinado M, Menjón-Beltrán S, et al. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy. Rev Esp Med Nucl. 2012;31(3):117-123.
64. Nason KS, Anderson BO, Byrd DR, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer. 2000;89(11):2187-2194.
65. Tafra L, Verbanac KM, Lannin DR. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am J Surg. 2001;182(4):312-315.
66. Fernández A, Cortés M, Benito E, et al. Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl Med Commun. 2001;22(4):361-366.
67. Julian TB, Patel N, Dusi D, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg. 2001;182(4):407-410.
68. Stearns V, Ewing CA, Slack R, et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol. 2002;9(3):235-242.
69. Brady EW. Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer. Breast J. 2002;8(2):97-100.
70. Lang JE, Esserman LJ, Ewing CA, et al. Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation. J Am Coll Surg. 2004;199(6):856-862.
71. Jones JL, Zabicki K, Christian RL, et al. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important. Am J Surg. 2005;190(4):517-520.
72. Yamamoto M, Mehta RS, Baick CH, et al. The predictive value of sentinel lymph node biopsy in locally advanced breast cancer patients who have undergone neoadjuvant chemotherapy. Am Surg. 2007;73(10):977-980.
73. Ozmen V, Unal ES, Muslumanoglu ME, et al. Axillary sentinel node biopsy after neoadjuvant chemotherapy. Eur J Surg Oncol. 2010;36(1):23-29.
74. Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999;230(1):72-78.
75. Khan A, Sabel MS, Nees A, et al. Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy. Ann Surg Oncol. 2005;12(9):697-704.
76. Newman EA, Guest AB, Helvie MA, et al. Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board. Cancer. 2006;107(10):2346-2351.
77. Chang JH, Vines E, Bertsch H, et al. The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience. Cancer. 2001;91(7):1231-1237.
78. El Saghir NS, El-Asmar N, Hajj C, et al. Survey of utilization of multidisciplinary management tumor boards in Arab countries. Breast. 2011;20(suppl 2): S70-S74.
79. Lamb BW, Brown KF, Nagpal K, et al. Quality of care management decisions by multidisciplinary cancer teams: a systematic review. Ann Surg Oncol. 2011; 18(8):2116-2125.
80. Saini KS, Taylor C, Ramirez AJ, et al. Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. Ann Oncol. 2012;23(4):853-859.
81. Haward R, Amir Z, Borrill C, et al. Breast cancer teams: the impact of constitution, new cancer workload, and methods of operation on their effectiveness. Br J Cancer. 2003;89(1):15-22.
82. Al Mushawa F, Tan MC, Margenthaler JA. Axillary staging prior to or after neoadjuvant systemic therapy? a single institutional experience. J Surg Oncol. 2010;102(5):404-407.
83. Lee MC, Eatrides J, Chau A, et al. Consequences of axillary ultrasound in patients with T2 or greater invasive breast cancers. Ann Surg Oncol. 2011;18(1): 72-77.